Laura J. Schumacher

October 17, 2026

CrowdStrike Shares Drop 7% Amid Cybersecurity Sector Rotation. CrowdStrike shares fell 7% on Friday as investors reassess the AI thesis and cybersecurity valuations. Recent commentary notes a split in the sector between platform and point solutions, with some stocks facing pressure. The stock is currently trading near its support level, reflecting broader market uncertainty.

October 17, 2026

RBC Lowers General Dynamics Price Target Amid Defense Sector Review. RBC Capital cut its price target for General Dynamics to $360 while maintaining a Sector Perform rating. This action occurs as broader defense stocks face pressure, with recent reports questioning if strong profitability can overcome weak momentum in the sector. The stock is currently trading near significant support levels, reflecting a cautious market stance on the company's near-term outlook.

October 16, 2026

AbbVie Gains from Oncology Trial News and Dividend Appeal. AbbVie’s recent oncology trial results suggest the stock may be undervalued, with a 51% risk reduction in diffuse large B‑cell lymphoma. Its 4.47% dividend yield and 16.4‑times earnings valuation attract income‑focused investors. Analysts compare AbbVie to peers like Pfizer and Merck, noting its outperformance this year. The stock sits near the top of its 52‑week range, adding context to the valuation debate.